Ibolya Czegle

Dr. Ibolya Czegle


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
VVViola Varga
Viola Varga
AGAndrás Gelley
András Gelley
EMEva Margittai
Eva Margittai
BBBuket Bagci
Buket Bagci
Edina A. Wappler-GuzzettaEdina A. Wappler-Guzzetta
Edina A. Wappler-Guzzetta
ICIbolya Czegle
Ibolya Czegle
Helicobacter pylori (H. pylori) infection is one of the most common bacterial infections worldwide. Its role in infection-associated cancers, such as gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma is well known. However, mitochondrial alterations in these malignancies are less documented. Mitochondria are key organelles, maintaining cellular homeostasis under normal and pathological conditions. They regulate complex cellular processes and play a key role in carcinogenesis and cancer progression in H. pylori-associated malignancies. This review summarizes the role of mitochondrial stress in H. pylori infection, gastric cancer, and MALT lymphoma.

29 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
AGAndrás Gelley
András Gelley
Noémi KériNoémi Kéri
Noémi Kéri
PBPéter Birinyi
Péter Birinyi
KKKinga Komka
Kinga Komka
VHVajk Hardy
Vajk Hardy
ICIbolya Czegle
Ibolya Czegle
Background: The official current guideline for Helicobacter pylori (H. pylori) eradication is to use tetracycline–bismuth-based protocols as first line treatment due to the increasing incidence of clarithromycin resistance in the last decade. The unavailability of tetracycline and bismuth-containing medicines, however, is an issue in many countries, limiting the routine use of these protocols. The value of using additional probiotics in eradication protocols is also unclear. Direct comparison data on the effect of available bismuth compounds and different probiotic strains on eradication outcome are limited. Goal: The aim of our investigation was to find optimal eradication protocols, supplementations and treatment duration for routine clinical use in our gastroenterology unit, located in a highly clarithromycin-resistant and tetracycline–bismuth-naïve area. Materials and Methods: We conducted a retrospective real-world data analysis of 402 H. pylori positive patients between 2016 and 2024. H. pylori infection was diagnosed using histological examination of gastroscopy samples obtained from the gastric antrum. For the evaluation of treatment success or failure, 14C breath tests and stool H. pylori antigen tests were performed. Data on patient characteristics and treatment protocols were collected from our electronic patient record system, and treatment success was compared between the different treatment regimes. Results: Despite the regional clarithromycin resistance, supplementing clarithromycin-based regimens with bismuth and probiotic during the 14-day treatment duration showed a high and comparable cure rate when compared to tetracycline-based regimens, which are the current first-line therapies. When tetracycline-based combination is available, it is recommended to use it with an additional probiotic to achieve the best possible outcome. Comparison of the effect of available bismuth preparations on treatment success showed no significant difference. Generally, probiotic-containing protocols are more successful, compared to those treatments without this supplement. There was no statistical difference in the cure rates amongst the four probiotic strains used, where sample size allowed statistical analysis. Furthermore, supplementation with probiotics Lactobacillus reuteri ATCC PTA 6475 or Lactobacillus reuteri Protectis® DSM 17938 showed promising high treatment success rates (85.2% and 100.0%, respectively) in our study.

7 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AGAndrás Gelley
András Gelley
Noémi KériNoémi Kéri
Noémi Kéri
PBPeter Birinyi
Peter Birinyi
KKKinga Komka
Kinga Komka
VHVajk Hardy
Vajk Hardy
ICIbolya Czegle
Ibolya Czegle
Background: The society guidelines for Helicobacter pylori (H. pylori) eradication, due to the increasing incidence of clarithromycin resistance in the last decade turned to rec-ommend the use tetracycline-bismuth-based protocols as first line treatment. The availability of tetracycline and bismuth containing medicines raising an issue in many countries, limiting the routine use of these protocols. Literature search showed une-quivocal information about the additional value of probiotics to eradication protocols. Direct comparison data of the effect of available bismuth compounds and different probiotic strains on eradication outcome are limited. Goal: The aim of our investigation was to find the optimal eradication protocols, sup-plementations and treatment duration for routine clinical use in our gastroenterology unit in a highly clarithromycin resistant and tetracycline-bismuth-naïve area. Materials and methods: We conducted a retrospective real-world data analysis of 402 cases between 2016-24. H. pylori infection was proved by histological examination of samples obtained from the antrum by gastroscopy, for the evaluation of treatment success or failure, 14C breath tests and stool H. pylori antigen tests were performed. Results: Despite regional clarithromycin resistance pattern, supplementation of the basic clarithromycin-based protocol with bismuth and probiotic in a treatment dura-tion of 14 days, lead to high and comparable success rates to the recommended first line tetracycline-based regimens. When tetracycline-based combination is available, it is recommended to use it with additional probiotic to achieve the best possible out-come. Comparison of the effect of available bismuth preparations on treatment success showed no significant difference. Generally, probiotic containing protocols are more successful, comparing to those treatments that not containing this supplement. No sta-tistical difference was found between the positive effect on success rates of those four probiotic strain, where sample size allowed statistical analysis. A promising result of two case series supplemented with a distinct probiotic combination (Lactobacillus reu-teri ATCC PTA 6475, Lactobacillus reuteri Protectis® DSM 17938) were found with 85.2% and 100.0% success rates.

26 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VVViola Varga
Viola Varga
AGAndrás Gelley
András Gelley
EMEva Margittai
Eva Margittai
BBBuket Bagci
Buket Bagci
Edina A. Wappler-GuzzettaEdina A. Wappler-Guzzetta
Edina A. Wappler-Guzzetta
ICIbolya Czegle
Ibolya Czegle
Helicobacter pylori (H. pylori) infection is recognized as one of the most common bacterial infections worldwide. Its role in infection-associated cancers, such as in gastric cancer and MALT-lymphoma, is well known. Mitochondrial alterations in these malignancies are less documented. Mitochondria is a key organelle in maintaining cellular homeostasis under normal and pathological conditions. They regulate complex cellular processes, and they are key players in carcinogenesis and cancer progression in these H.pylori-associated malignancies. In this review, we summarize the role of mitochondrial stress in H. pylori infection, in gastric cancer, and MALT-lymphoma.

Verified
Journal Article
Open access
PDF file
Edina A. Wappler-GuzzettaEdina A. Wappler-Guzzetta
Edina A. Wappler-Guzzetta
EMEva Margittai
Eva Margittai
KVKrisztina Veszelyi
Krisztina Veszelyi
SPShanel Pickard
Shanel Pickard
CMCaroline Merwin
Caroline Merwin
ICIbolya Czegle
Ibolya Czegle
Epithelial ovarian cancer is one of the most lethal gynecological malignancies worldwide. Its development strongly depends on several genetic and environmental factors, with metabolic components and cellular redox homeostasis alterations playing a significant a role in its development and disease progression. In this review, we summarize the contribution of mitochondrial and endoplasmic reticulum (ER) stress in the pathogenesis of epithelial ovarian cancer along with their role as potential biomarkers and therapeutic targets, including proteins of glucose metabolism, mitochondrial fission and fusion, mitophagy, membrane-associated ring-CH-type finger 5 (MARCH5), A-kinase anchoring proteins (AKAPs), proteins regulating mitochondrial Ca2+ homeostasis, mitochondrial unfolded protein response (UPRmt) proteins, activating transcription factors (ATFs), CCAAT enhancer binding protein (C/EBP) homologous protein (CHOP), ‘mitokines’, GRP75, and GRP78. Although many of these potential targets are in preclinical phase, they have a high potential to become valuable alternative or additive treatments for epithelial ovarian cancers.